Zosano Pharma (ZSAN) Rating Increased to Sell at ValuEngine

Zosano Pharma (NASDAQ:ZSAN) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Wednesday.

Shares of Zosano Pharma (NASDAQ ZSAN) opened at $4.77 on Wednesday. Zosano Pharma has a one year low of $4.25 and a one year high of $70.80. The company has a market cap of $198.29, a P/E ratio of -0.20 and a beta of 1.89.

Zosano Pharma (NASDAQ:ZSAN) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($4.00) EPS for the quarter, missing analysts’ consensus estimates of ($3.00) by ($1.00). equities analysts forecast that Zosano Pharma will post -18 earnings per share for the current year.

In other news, Director Kenneth Greathouse bought 55,000 shares of the firm’s stock in a transaction on Wednesday, December 6th. The shares were bought at an average price of $0.61 per share, for a total transaction of $33,550.00. Following the purchase, the director now owns 200,000 shares in the company, valued at $122,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have acquired 200,000 shares of company stock worth $123,450. 2.83% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. raised its stake in Zosano Pharma by 8.3% during the 4th quarter. Victory Capital Management Inc. now owns 257,673 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 19,680 shares during the period. Northern Trust Corp raised its stake in Zosano Pharma by 591.4% during the 2nd quarter. Northern Trust Corp now owns 79,234 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 67,774 shares during the period. Finally, Vanguard Group Inc. raised its stake in Zosano Pharma by 20.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,217,323 shares of the biotechnology company’s stock worth $1,716,000 after acquiring an additional 209,251 shares during the period.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/07/zosano-pharma-zsan-rating-increased-to-sell-at-valuengine.html.

Zosano Pharma Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit